M. Peterson

发表

Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

J. Pérez-Ruixo, L. Gibiansky, A. Chow, 2012, Clinical Pharmacokinetics.

Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors

J. Pérez-Ruixo, A. Chow, S. Doshi, 2012, Clinical Cancer Research.

Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

J. Pérez-Ruixo, A. Chow, S. Doshi, 2011, Clinical pharmacokinetics.

Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women

Paolo Vicini, Mark C. Peterson, Marc R. Gastonguay, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors

Yow-Ming C Wang, A. Chow, Bing‐Bing Yang, 2009, Journal of clinical pharmacology.

AStudy of the Biological ReceptorActivator of Nuclear Factor-K B Ligand Inhibitor , Denosumab , in PatientswithMultipleMyeloma or BoneMetastases fromBreast Cancer

J. Body, R. Coleman, P. Bekker, 2006 .

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

J. Body, R. Coleman, P. Bekker, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chapter 86. Radiotherapy of Skeletal Metastases

P. Gascón, G. Steger, R. Berardi, 2008 .

Single‐ and multiple‐dose pharmacokinetics of tofacitinib in healthy Chinese volunteers

Haihong Shi, S. Krishnaswami, C. Alvey, 2015, Clinical pharmacology in drug development.

Selection of a phase 3 dose regimen for denosumab based on pharmacokinetic (PK), pharmacodynamic (PD), and safety data from multiple subcutaneous (SC) dosing regimens in breast cancer patients (pts) with bone metastases (BM).

M. Peterson, R. Dansey, A. Kinsey, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extension of a Multiscale Model of Calcium Homeostasis and Bone Remodeling to Include the Progressive Effects of Estrogen Loss During Menopause Transition.

M. Gastonguay, M. Riggs, M. Peterson, 2010 .

Evidence for the involvement of blood flow-related mechanisms in the ovulatory process of the rat.

M. Brännström, P. Janson, M. Mikuni, 2000, Human reproduction.

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

P. Gascón, G. Steger, J. Body, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A PHYSIOLOGICALLY-BASED, MULTISCALE MODEL USED TO PREDICT PROGRESSIVE BONE MINERAL DENSITY LOSS DUE TO CHRONIC RENAL DISEASE

M. Gastonguay, M. Riggs, M. Peterson, 2010 .

Denosumab in Postmenopausal Women with Low Bone Mineral Density

P. Miller, M. Peacock, M. McClung, 2007 .

Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model

M. Riggs, M C Peterson, M M Riggs, 2012, CPT: pharmacometrics & systems pharmacology.

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling.

Matthew M Riggs, M. Riggs, Mark C Peterson, 2010, Bone.

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

P. Gascón, G. Steger, J. Body, 2008, Clinical Cancer Research.

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib

C. Banfield, E. Soto, M. Peterson, 2020, CPT: pharmacometrics & systems pharmacology.

Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients

Donald E Mager, D. Mager, Mark C Peterson, 2008, Journal of Pharmacology and Experimental Therapeutics.

AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development

Steven W. Martin, Shiew-Mei Huang, R. Evers, 2011, The AAPS Journal.

Multiscale Physiology‐Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function

Marc R Gastonguay, M. Gastonguay, Matthew M Riggs, 2012, Journal of clinical pharmacology.

Evaluating the Role of Janus Kinase Pathways in Platelet Homeostasis Using a Systems Modeling Approach

S. Nayak, C. Banfield, Sarita Koride, 2019, CPT: pharmacometrics & systems pharmacology.

“Fit-for-Purpose” Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies

Binodh DeSilva, Daniel Burns, Jean W. Lee, 2009, The AAPS Journal.

Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors

J. Pérez-Ruixo, A. Chow, S. Doshi, 2012, Clinical Cancer Research.